The nation of Zimbabwe has rejected a significant US healthcare agreement valued at 367 million US dollars (£272m) spanning five years due to Washington's demand for sensitive biological samples.
The decision became public following a government memo from December was disclosed, indicating that President Emmerson Mnangagwa felt the agreement was "lopsided".
A government spokesperson has since stated that the US was seeking genetic material for research and commercial purposes but was not willing to guarantee the resulting advantages from any future vaccines.
"We will now turn to the difficult and regrettable process of ending our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy indicated the US had provided more than $1.9bn for health programmes to Zimbabwe over the last two decades.
A doctors' association in Zimbabwe has called for further talks to secure a deal agreeable to both sides so the country's vital HIV treatment initiative can proceed.
Wider Implications
This rejection follows a comparable situation in Kenya, where a high court blocked a related health funding agreement following legal challenges were filed about the safety of Kenyans' medical information.
Since resuming the presidency last year, US President Donald Trump has slashed foreign aid and closed the US Agency for International Development (USAID).
The agency had administered assistance for the US government, but Trump stated its spending was "wasteful" and his administration was seeking government-to-government deals to boost openness and accountability.
Based on reports, Sixteen nations in Africa have so far agreed to these new health pacts, constituting more than $18.3bn of fresh investment.
Details of the Declined Deal
The funds for Zimbabwe would have funded "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this collaboration could have provided immense benefits for Zimbabwean communities, especially the 1.2 million presently receiving HIV treatment through US-supported initiatives," Tremont added.
However, government spokesperson Nick Mangwana argued the proposed deal was "unequal".
"The proposal required Zimbabwe to provide its genetic material and health information indefinitely, without any equivalent assurance of benefiting from any medical innovations – such as vaccines, diagnostics, or treatments – that might result from that shared data," his statement read.
"Effectively, our nation would supply the basic resources for scientific discovery without any assurance that the resulting innovations would be available to our citizens should a new pandemic arise."
National Interest and International Frameworks
He also said that the American exit from the World Health Organization (WHO) and its pursuit of bilateral deals were upending frameworks already set up through the international organization.
Mangwana gave as an example its Pandemic Benefit-Sharing scheme created to manage future pandemics.
"This system is intended to guarantee that when a country provides its information, the benefits – such as vaccines and treatments – are shared equitably, not commercialised exclusively by those with the capability to create them."
These objections over the US deal "must not be interpreted as opposition to America," he added.
"We welcome further dialogue with our US partners on how subsequent collaboration might be arranged in a manner that honours the independence and dignity of each country."
Health Experts Response
The Zimbabwe College of Public Health Physicians (ZCPHP) said it understood the official position, but suggested that negotiations must proceed given that much of the nation's Aids initiatives were funded by external financing.
"In cases where specific concerns exist, including those relating to data governance or agreement terms, these can frequently be addressed through technical clarification and negotiated safeguards," it said.
The halted deal underscores the ongoing challenges between receiving vital foreign assistance and protecting national sovereignty in an ever more data-driven world.